Status:
COMPLETED
Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy
Lead Sponsor:
Allergan
Conditions:
Vitrectomy
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study will evaluate the pharmacokinetics of brimonidine following a single intravitreal administration of the 200 ug or 400 ug Brimonidine Tartrate Posterior Segment Drug Delivery System in patie...
Eligibility Criteria
Inclusion
- Plan on having a pars plana vitrectomy for repair of a posterior segment condition (eg, epiretinal membrane, macular hole, vitreomacular traction)
- Visual acuity in the non-study eye better than 20/200
Exclusion
- History of pars plana vitrectomy or retinal detachment surgery in the study eye
- Surgery or laser treatment in the study eye within 3 months
- Use of brimonidine, apraclonidine or other topical alpha-2-agonist in either eye within 2 weeks
- Intraocular infection or inflammation
Key Trial Info
Start Date :
December 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01229410
Start Date
December 1 2010
End Date
October 1 2011
Last Update
August 5 2013
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Salt Lake City, Utah, United States
2
Prague, Czechia